Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Twist Bioscience Corp (TWST) reported an insider transaction by its Senior Vice President, Chief Legal Officer & Corporate Secretary. On 11/21/2025, the reporting person sold 757 shares of Twist Bioscience common stock at a price of $26.5035 per share. After this transaction, the insider beneficially owned 145,402 shares directly.
The company explains that these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units. The sale was executed under the issuer’s equity incentive plan using a mandated “sell to cover” arrangement, meaning the transaction did not represent a discretionary trade or a change in the insider’s investment view.
Twist Bioscience Corp (TWST) reported an insider transaction by its President and COO on a Form 4. On 11/21/2025, the officer sold 1,776 shares of common stock at a price of $26.5035 per share. After this transaction, the officer beneficially owned 332,883 shares directly.
The company explains that these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units. The sale was mandated under the company’s equity incentive plans as a "sell to cover" transaction and is described as not a discretionary trade by the reporting person.
Twist Bioscience Corp (TWST) reported a small insider transaction by its Senior Vice President of Human Resources, Paula Green. On 11/21/2025, Green sold 598 shares of common stock at a price of $26.5035 per share. After this transaction, she beneficially owned 167,789 shares directly.
The company explains that the sale was made to cover tax withholding obligations triggered by the vesting of Restricted Stock Units. These transactions are described as mandated under Twist Bioscience’s equity incentive plans through a “sell to cover” election, meaning they are not discretionary trades initiated by the executive for portfolio reasons.
Twist Bioscience Corporation's Chief Financial Officer reported an automatic sale of company stock to cover taxes. On 11/21/2025, the reporting person sold 887 shares of common stock at a price of $26.5035 per share. The filing explains that these shares were sold under a mandatory "sell to cover" arrangement tied to the vesting of Restricted Stock Units, meaning the transaction was not a discretionary trade. After this tax-related sale, the officer beneficially owned 142,769 shares of Twist Bioscience common stock in direct ownership.
Twist Bioscience Corp (TWST) reported an insider transaction by its Chief Executive Officer and director, Emily M. Leproust. On 11/21/2025, she disposed of 2,663 shares of common stock at a price of $26.5035 per share in a sale coded "S." This sale was made to cover tax withholding obligations triggered by the vesting of restricted stock units, and is described as a mandatory "sell to cover" under the company’s equity incentive plans rather than a discretionary trade.
Following this transaction, Leproust beneficially owned 878,173 shares of common stock, held directly. She also holds several employee stock options with various exercise prices and vesting schedules, including performance stock options granted on September 1, 2020 that vested and became exercisable on December 19, 2022 after meeting specified performance criteria.
Twist Bioscience Corp (TWST) reported insider share sales by its Chief Accounting Officer. The reporting person sold 229 shares of common stock on 11/21/2025 at a price of $26.5035 per share and 822 shares on 11/24/2025 at a price of $28.7095 per share. After these transactions, the officer beneficially owned 66,143 shares of Twist Bioscience common stock in direct ownership.
According to the explanation, the 229 and 822 shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plans, and the sales did not represent discretionary trades by the officer.
Twist Bioscience Corp (TWST) reported a new equity award to its Chief Executive Officer and director, Emily M. Leproust. On 11/18/2025, she received 146,914 shares of common stock in the form of restricted stock units at a reported price of
The RSU grant vests over four years, with 1/16 of the total vesting on each quarterly anniversary of
Twist Bioscience Corp (TWST) reported a routine insider equity grant to its President and COO, Patrick John Finn. On 11/18/2025, he received 68,740 shares of common stock in the form of restricted stock units (RSUs) at a price of $0 per share. Following this grant, he beneficially owned 334,659 shares of Twist Bioscience common stock in total.
The RSU award vests over four years, with 1/16 of the RSUs vesting on each quarterly anniversary of November 20, 2025, subject to his continued service. This structure ties a portion of the executive’s compensation to the company’s long-term performance and his ongoing role.
Twist Bioscience Corp (TWST) reported that its Chief Financial Officer received a grant of 32,648 restricted stock units (RSUs) of common stock on 11/18/2025. The RSUs were recorded at a price of $0 because they are equity awards rather than open‑market purchases.
Following this grant, the CFO beneficially owns 143,656 shares of Twist Bioscience common stock in total. The RSU award vests over four years: 1/16 of the total RSUs vest on each quarterly anniversary of November 20, 2025, for a total vesting period of 48 months, as long as the executive remains in continuous service through each vesting date.
Twist Bioscience Corp (TWST) officer Dennis Cho reported a grant of 25,465 restricted stock units (RSUs) of common stock at a price of $0 per share. After this equity award, he beneficially owns 146,159 shares of Twist Bioscience common stock in total.
The RSU award vests over four years, with 1/16 of the RSUs vesting on each quarterly anniversary of November 20, 2025, for a total vesting period of 48 months, subject to his continuous service with the company. Cho serves as Senior Vice President, Chief Legal Officer & Corporate Secretary, and this Form 4 reflects routine insider equity compensation.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
